Pyrogen Testing Market to Surpass US$ 2,220.5 Million by 2027

Global Pyrogen Testing Market, By Test Type (Limulus Amoebocyte Lysate (LAL) Test, TAL Test, Monocyte Activation Test (MAT), Rabbit Pyrogen Test (RPT), and Recombinant Factor C Assay (rFC)), By Product Type (Instruments, Kits, and Reagents), By End User (Pharmaceutical and Biotech Companies, Food and Beverages Companies, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 979.7 million in 2020 and is expected to exhibit a CAGR of 12.4% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Increasing approvals of new testing technologies by regulatory authorities is expected to drive growth of the global pyrogen testing market over the forecast period. For instance, in May 2018, Indian Pharmacopoeia Commission (IPC), an autonomous institution of Ministry of Health and Family Welfare to set standards of drugs in India, approved the modern, animal-free tests for drug manufacturers. The Indian Pharmacopoeia Commission (IPC) approved bacterial endotoxin test or monocyte activation test, which can be carried out in test tubes.

Global Pyrogen Testing Market – Impact of Coronavirus (Covid-19) Pandemic

Regulatory authorities are taking various actions to monitor and encourage the development of therapeutics for COVID-19 treatment. For instance, on April 20, 2020, the U.S. Food and Drug Administration (FDA) launched a special emergency program, Coronavirus Treatment Acceleration Program (CTAP), for possible coronavirus therapies. The Coronavirus Treatment Acceleration Program (CTAP) utilizes all the available methods to provide new treatments to patients as quickly as possible and simultaneously find out whether these methods are helpful or harmful.

Moreover, increasing research and development activities in order to develop drugs for COVID-19 treatment is expected to drive growth of the pyrogen testing market over the forecast period. According to the Coronavirus Treatment Acceleration Program (CTAP) dashboard created by the U.S. Food and Drug Administration (FDA), as of July 31, 2020, more than 570 drug development programs are in planning stage and so far, the U.S. Food and Drug Administration (FDA) has reviewed around 270 trials.

Browse 23 Market Data Tables and 26 Figures spread through 153 Pages and in-depth TOC on “Pyrogen Testing Market”- Global Forecast to 2027, By Test Type (Limulus Amoebocyte Lysate (LAL) Test, TAL Test, Monocyte Activation Test (MAT), Rabbit Pyrogen Test (RPT), and Recombinant Factor C Assay (rFC)), By Product Type (Instruments, Kits, and Reagents), By End User (Pharmaceutical and Biotech Companies, Food and Beverages Companies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global pyrogen testing market, click the link below:

https://www.coherentmarketinsights.com/market-insight/pyrogen-testing-market-243

Increasing number of approvals for new molecule entities (NMEs) by regulatory agencies is expected to bolster the market growth over the forecast period. In 2018, the U.S. Food and Drug Administration (FDA) approved 59 new molecule entities, which enable new treatment options for patients and advances in health care for the American people.                               

Key Takeaways of the Global Pyrogen Testing Market:

• The global pyrogen testing market is expected to exhibit a CAGR of 12.4% over the forecast period, owing to increasing expenditure on pharmaceuticals. According to the European Federation of Pharmaceutical Industries and Association (EFPIA) report, 2018, an estimated US$ 48,111 million and US$ 82,418 million pharmaceutical expenditure was recorded in 2015 and 2016 respectively, in the U.S.
• Among test type, the limulus amoebocyte lysate test segment held a dominant position in the pyrogen testing market in 2019, owing to its reliability and reproducibility in detection
• Among end user, pharmaceutical and biotech companies segment held a dominant position in the pyrogen testing market in 2019, as the requirement of pyrogen testing is majorly in pharmaceutical and biotech companies
• Key players operating in the global pyrogen testing market include Thermo Fisher Scientific, Merck KGaA, Lonza Group, Associates of Cape Cod Inc., Charles River Laboratories Inc., GenScript, WuXi PharmaTech (Cayman), Inc., bioMérieux, Wako Chemicals USA, Inc., Sanquin, Ellab A/S, and Pyrostar